66.07

1.33% -0.89

Arrowhead Pharmaceuticals Inc (ARWR)

Overview News Price History Option Chain Financials Why ARWR Down? Discussions Forecast Stock Split

Arrowhead Pharmaceuticals Inc stock is traded at $66.07, with a volume of 1.63M. It is down -1.33% in the last 24 hours and down -23.82% over the past month. Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

Previous Close:

$66.96

Open:

$67

24h Volume:

1.63M

Relative Volume:

0.75

Market Cap:

$9.33B

Revenue:

$622.01M

Net Income/Loss:

$-271.86M

P/E Ratio:

-30.75

EPS:

-2.1484

Net Cash Flow:

$-45.87M

1W Performance:

-2.47%

1M Performance:

-23.82%

6M Performance:

+17.42%

1Y Performance:

+101.25%

1-Day Range:

$65.46

$67.45

1-Week Range:

$65.46

$72.49

52-Week Range:

$31.45

$95.49

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name

Arrowhead Pharmaceuticals Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

626-696-4702

Address

177 E COLORADO BLVD, PASADENA, CA

Employee

711

Twitter

@ArrowheadPharma

Next Earnings Date

2026-08-04

Latest SEC Filings

ARWR's Discussions on Twitter

Compare ARWR vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARWR Arrowhead Pharmaceuticals Inc	66.07	9.33B	622.01M	-271.86M	-45.87M	-2.1484
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-05-24	Initiated	Goldman	Neutral
Dec-04-23	Initiated	BofA Securities	Buy
Sep-19-23	Initiated	Citigroup	Neutral
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform
Jan-19-22	Resumed	Goldman	Buy
Aug-06-21	Reiterated	Chardan Capital Markets	Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-05-21	Reiterated	H.C. Wainwright	Buy
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	UBS	Buy
Nov-19-20	Initiated	Citigroup	Buy
May-13-20	Initiated	RBC Capital Mkts	Outperform
May-08-20	Upgrade	Oppenheimer	Perform → Outperform
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-24-20	Upgrade	SVB Leerink	Underperform → Mkt Perform
Mar-17-20	Initiated	Goldman	Neutral
Jan-21-20	Initiated	SVB Leerink	Underperform
Dec-13-19	Initiated	Oppenheimer	Perform
Nov-29-19	Reiterated	Chardan Capital Markets	Buy
Nov-27-19	Reiterated	B. Riley FBR	Buy
Nov-25-19	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-24-19	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-22-19	Reiterated	Chardan Capital Markets	Buy
Oct-03-19	Initiated	Robert W. Baird	Outperform
Sep-07-18	Upgrade	B. Riley FBR	Neutral → Buy
Sep-06-18	Reiterated	Chardan Capital Markets	Buy
Aug-08-18	Reiterated	Cantor Fitzgerald	Overweight
Jul-02-18	Reiterated	Chardan Capital Markets	Buy

View All

Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News

Sep 24, 2026

ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Stocktwits

Sep 24, 2026

ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near - finance.yahoo.com

Sep 24, 2026

Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating By Investing.com - Investing.com South Africa

Sep 24, 2026

Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating - Investing.com Canada

Sep 24, 2026

Sep 23, 2026